Does a DSIP nasal spray exist?

Yes, in a limited sense. One small human paper from 2001 reported an intranasal DSIP experiment, and online sellers advertise spray products. But the paper measured an electrical brain response rather than sleep, and it did not establish a validated commercial formulation. A spray being sold is not evidence that its absorption, contents, or sleep effects have been demonstrated.

Has intranasal DSIP been studied in humans?

Yes. The published human record includes a 2001 letter reporting a P300 brain-response change after intranasal DSIP. It was not a sleep-outcome trial and did not publish the blood-concentration measurements needed to describe nasal absorption. That narrow experiment is useful evidence that the route was tried, but not that a DSIP spray improves sleep.

Does DSIP spray help with sleep?

We do not know. No published human trial has shown that a nasal DSIP formulation improves falling asleep, staying asleep, or next-day functioning. The older human sleep studies mostly used IV DSIP and produced inconsistent results in very small groups. Those findings cannot be copied onto a spray because changing the route can change both absorption and exposure.

Does Promise offer DSIP as a nasal spray?

No. Promise’s current DSIP page lists a compounded injectable vial for subcutaneous use at 1 mg per mL. It does not list a nasal product. Formulations can vary by pharmacy and prescription, so the label on the medication dispensed controls; a reader should not infer a spray from studies or products found somewhere else online.

What did the July 2026 DSIP vote mean?

It was an advisory recommendation, not a final rule or a drug-approval decision. The committee did not recommend emideltide free base or emideltide acetate for the 503A Bulks List after identical 6–7–1 votes. FDA says advisory recommendations are nonbinding. A licensed provider and patient can still make an individual prescribing decision about a compounded formulation.

DSIP Nasal Spray: What the Human Research Says

A DSIP nasal spray has been used in one published human experiment. That is the plain answer. But the study did not test sleep, and it did not measure how much DSIP reached the blood or brain. Most human sleep research used intravenous DSIP, meaning it went directly into a vein.

So two claims can be true at once: intranasal DSIP—DSIP given through the nose—does appear in human literature, and there still is not a human nasal study that validates a DSIP spray for sleep.

Is there human research on a DSIP nasal spray?

Yes, but it is remarkably thin. A three-page 2001 letter in the Journal of Clinical Psychopharmacology was titled “Intranasal administration of delta sleep-inducing peptide increases P300”. P300 is a brief electrical brain response recorded during an attention task. It is not a measure of falling asleep, staying asleep, or waking rested.

That paper matters because it corrects the sweeping statement that DSIP has never been given through the nose in people. It does not establish a useful spray. The study did not report a human nasal pharmacokinetic profile, or PK—the measurements that show how much of a substance enters the body, where it goes, and how quickly it clears. It did not measure sleep outcomes at all.

There is intranasal animal work too. A 2021 study in rats tested DSIP after an experimentally induced stroke and measured motor recovery and brain changes. That was a stroke model in animals, not a sleep study in people. It cannot answer whether a nasal spray helps human sleep.

What the one nasal paper does not tell us

A nasal product is more than a peptide mixed into liquid. The concentration, solution, spray pump, droplet size, and condition of the nasal lining can all affect what is delivered and absorbed. Without human DSIP blood-concentration data, a number printed on a spray bottle cannot tell us the exposure inside the body.

This is where gray-market marketing tends to run ahead of the evidence. A seller can point to the word “intranasal” in a paper and skip what the researchers actually measured. The missing pieces are the ones a patient would care about: reliable absorption, a tested finished formulation, sleep results, and a systematic safety record for that route.

The distinction also keeps the deeper questions in their proper places. What DSIP is explains the peptide and its history, while the guide to possible DSIP benefits examines the outcomes researchers have actually studied. Neither turns a route mention into proof of a nasal sleep product.

Why research cannot be moved from one route to another

Intravenous, subcutaneous, and nasal delivery are not interchangeable. A peptide placed in a vein starts in the bloodstream. A subcutaneous injection goes into the tissue under the skin. A nasal product first has to survive the formulation, device, and nasal surface before any useful amount can be absorbed.

The same caution applies across compounds. Semax and Selank have their own intranasal literature, but they are different peptides; that research cannot fill DSIP’s evidence gap. Promise’s Semax / Selank option is a separate injectable combination, so its route and evidence deserve a separate provider conversation too.

The human sleep studies mostly used intravenous DSIP

The older sleep literature is small and mixed. A 1983 overview described five human studies using single or repeated intravenous injections with participants and researchers kept unaware of the treatment assignment (Schneider-Helmert, Neuropsychobiology). Some early reports described changes in sleep measures, but later controlled work did not produce a clean, repeatable answer.

In one 1987 controlled crossover study, the same six people with chronic insomnia received intravenous DSIP and placebo during separate periods, without knowing which was being used. The researchers found no significant differences from baseline or placebo on several sleep measures and judged the effects to have little clinical significance. Six people is far too small a group for a confident treatment conclusion.

FDA’s 2026 evidence presentation reached the same practical reading: the intravenous results were preliminary and inconsistent, with no evidence for the nominated subcutaneous route in chronic insomnia (FDA presentation, July 24, 2026). None of that supplies the missing nasal PK or a nasal sleep trial. For a separate look at how prescribers think about amount, timing, and route, see DSIP dosage.

What changed at FDA in July 2026

As of September 9, 2026, the day this article was written, the freshest relevant federal action was the July 24 Pharmacy Compounding Advisory Committee vote on emideltide, FDA’s name for DSIP. Members voted 6 yes, 7 no, and 1 abstention on both the free-base and acetate forms—two chemical versions of the peptide—so neither was recommended for the 503A Bulks List. That list covers certain bulk substances a pharmacy may use to prepare medication for an individual prescription under section 503A.

The FDA meeting record links the official webcast and explains that advisory recommendations are nonbinding. This was not a final rule or an approval decision. DSIP is not FDA-approved.

A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. The vote is relevant context, not a substitute for an individual medical review.

What Promise actually offers

Promise’s current DSIP product page lists an injectable vial for subcutaneous use at 1 mg per mL, not a nasal spray. Formulations vary by pharmacy and prescription, so the label on the medication actually dispensed is the source of truth. Nothing on the current page supports assuming a spray will arrive.

A prescription route also gives the patient something a gray-market bottle does not: a named clinical process, a licensed U.S. compounding pharmacy, documented dispensing, and a care team to contact with a problem. It does not make thin research stronger. It makes the decision and the product accountable.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The provider can weigh the exact formulation, current medications, sleep symptoms, and better-established explanations for poor sleep before prescribing or declining.